Publication date: Available online 22 May 2019
Source: Journal of Plastic, Reconstructive & Aesthetic Surgery
Author(s): Bilal Fakim, Lyndsey Highton, Ashu Gandhi, Richard Johnson, John Murphy
Summary
Background
In 2015, Artia™ (Lifecell, NJ), a new porcine Acellular Dermal Matrix (ADM), was introduced at our unit. As clinical studies of its use in breast reconstruction are lacking, the purpose of this prospective study was to assess outcome data for patients who had Artia™ assisted breast reconstruction. We compared this data to other studies of non-human ADMs in widespread use from the literature.
Methods
All consecutive patients who had Artia™ assisted breast reconstruction between July 2016 and February 2018 were identified. A prospective database was maintained including patient demographics, type of reconstruction, and type of implant, oncological data if applicable, complication rates and adjuvant treatment delays.
Results
51 patients undergoing 83 implant-based breast reconstructions with Artia™ were included in the study. Of the 83 reconstructions, 62% were performed following risk reducing mastectomy, 28% following therapeutic mastectomy and 10% for revision procedures. Over a mean 276-day follow-up period, the overall complication rate was 10.8%, including 6 breasts (7.2%) developing seromas requiring aspiration, 1 breast developing a haematoma (1.2%) and 2 implant losses (2.4%) in a single patient following neo-adjuvant chemotherapy. There were no cases of wound dehiscence or erythema/red breast syndrome.
Conclusion
This is one of the first studies demonstrating that Artia™ assisted implant- based breast reconstruction is associated with low and acceptable early complication rates. The results are promising and are comparable to our experience using established ADMs, with an implant loss rate of 4.9% in over 500 ADM assisted implant reconstructions.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου